样式: 排序: IF: - GO 导出 标记为已读
-
The pharmacological management of asthma in adults: 2023 update Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-03-18 Maria Gabriella Matera, Barbara Rinaldi, Rosa Annibale, Vito De Novellis, Mario Cazzola
The pharmacotherapy of asthma is a dynamic process that changes as our knowledge of the underlying pathophysiology and treatment of this disease continues to evolve. This implies the need for conti...
-
An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-03-18 Divisha Sharma, Jose A Vazquez
Invasive fungal infections, especially candidemia and invasive candidiasis, continue to cause substantial morbidity and mortality. In addition, the emergence of drug-resistant Candida species, nota...
-
Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-03-15 Alessandro Costa, Emilia Scalzulli, Ida Carmosino, Claudia Ielo, Maria Laura Bisegna, Maurizio Martelli, Massimo Breccia
Despite the notable success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML), a subset of patients experiences resistance, or relapse after discontinuation. This chal...
-
Therapeutic strategies in FcγIIA receptor-dependent thrombosis and thromboinflammation as seen in heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT) Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-03-12 Luisa Müller, Venkata A.S. Dabbiru, Linda Schönborn, Andreas Greinacher
Fcγ-receptors (FcγR) are membrane receptors expressed on a variety of immune cells, specialized in recognition of the Fc part of immunoglobulin G (IgG) antibodies. FcγRIIA-dependent platelet activa...
-
Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-03-11 Jean-Baptiste Belge, Bernard G.C.C. Sabbe
Non-adherence to medication significantly affects bipolar disorder outcomes. Long-Acting Injectable antipsychotics show promise by ensuring adherence and averting relapses.This narrative review sou...
-
Novel pharmacotherapeutic options for the treatment of postural orthostatic tachycardia syndrome Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-03-11 Anthony Lyonga Ngonge, Christabel Nyange, Jalal K. Ghali
Postural tachycardia syndrome (POTS) is a disorder characterized by a constellation of symptoms including lightheadedness, fatigue, and palpitations when upright, associated with an increase in the...
-
GLP-1 receptor agonists in the treatment of diabetic non-alcoholic steatohepatitis patients Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-03-08 Ernest A. Adeghate
Nonalcoholic fatty liver disease (NAFLD) is the most common hepatic disease affecting almost 30% of the world population. Approximately 25% of people with NAFLD develop nonalcoholic steatohepatitis...
-
Pharmacological management of invasive mold infections in solid organ transplant recipients Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-03-04 Mario Fernández-Ruiz
Solid organ transplant (SOT) recipients face an increased susceptibility to invasive fungal infection (IFI) due to filamentous fungi. Post-transplant invasive aspergillosis (IA) and mucormycosis ar...
-
BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-26 Panagiotis I. Georgianos, Christodoula Kourtidou, Maria Divani, Vassilios Liakopoulos
Published in Expert Opinion on Pharmacotherapy (Ahead of Print, 2024)
-
Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-23 Lance V Watkins, Seungyoun Moon, Lisa Burrows, Samuel Tromans, Julian Barwell, Rohit Shankar
Fragile X Syndrome (FXS) is the most common inherited cause of Intellectual Disability. There is a broad phenotype that includes deficits in cognition and behavioral changes, alongside physical cha...
-
Impact of bladder cancer family history on the prognosis of patients with Non-Muscle Invasive bladder cancer Treated with Bacillus Calmette-Guerin (BCG) Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-23 Mohamad Abou Chakra, Igor Duquesne, Michael Peyromaure, Sarah L. Mott, Mohamad Moussa, Michael A O’Donnell
To evaluate the impact of having first-degree relatives (FDR) with bladder cancer (BC) among non-muscle invasive bladder cancer (NMIBC) patients treated with Bacillus Calmette – Guérin (BCG) on the...
-
Simnotrelvir as a potential treatment for COVID-19 Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-23 Matthew W. McCarthy
Simnotrelvir is a selective 3-chymotrypsin-like oral protease inhibitor with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).On 18 January 2024, results of a double-bl...
-
An update on the current and emerging pharmacotherapy for the treatment of human ascariasis Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-19 Kam Lun Hon, Alexander K.C. Leung
Globally, Ascaris lumbricoides is the commonest helminthic infection that affects people in underdeveloped countries and returning immigrants in industrialized nations. This article aims to provide...
-
Patterns of corticosteroid use among remdesivir and matched patients and associated clinical outcomes in hospitalized COVID-19 patients Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-16 Ivan Papic, Petra Bistrovic, Tatjana Keres, Maja Ortner Hadziabdic, Marko Lucijanic
We aimed to investigate patterns of corticosteroid use and their relationship with remdesivir use and clinical outcomes in a large real-life cohort of COVID-19 patients treated in a tertiary-level ...
-
Parkinson’s disease psychosis management: an evidence based, experience informed, pragmatic approach Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-12 Joseph H. Friedman
Psychotic symptoms in people with Parkinson’s disease (PD) have attracted increasing. Recommendations on treating psychosis often fail to take into account what psychotic symptoms require treatment...
-
An update review of new therapies in sickle cell disease: the prospects for drug combinations Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-12 Sanne Lugthart, Catarina Ginete, Patience Kuona, Miguel Brito, Baba Psalm Duniya Inusa
Sickle cell disease (SCD) is an inherited disorder characterized by polymerization of deoxygenated hemoglobin and microvascular obstruction. Generalized, it affects millions of people over 85% from...
-
Efficacy and safety of low-dose oral minoxidil in the management of androgenetic alopecia Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-05 Aditya K. Gupta, Mesbah Talukder, Avner Shemer
Treating alopecia can be challenging. The available treatments are topical minoxidil, low-dose oral minoxidil (LDOM), and 5-α reductase inhibitors like finasteride and dutasteride. Only topical min...
-
Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play? Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-01 Carel Le Roux, Alvin Mondoh
Obesity, marked by abnormal fat accumulation, poses significant health risks, necessitating effective therapeutic interventions. The focus of this review is to elucidate the importance of glucagon-...
-
The pharmacotherapeutic management of allergic rhinitis in people with asthma Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-01 Ludger Klimek, Pascal Werminghaus, Ingrid Casper, Mandy Cuevas
Up to 90% of asthmatic patients have comorbid allergic rhinitis (AR). Although appropriate therapy of AR can improve asthma symptoms and management, AR is often underdiagnosed and under-treated in ...
-
Testosterone replacement therapy: clinical considerations Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-01 Patrick M. Luther, Noah J. Spillers, Norris C. Talbot, Evan S. Sinnathamby, Dakota Ellison, Rucha A. Kelkar, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D. Kaye
As an increasingly popular therapeutic option, testosterone replacement therapy (TRT) has gained significant notoriety for its health benefits in indicated populations, such as those suffering from...
-
Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-01 Aditya K. Gupta, Shruthi Polla Ravi, Mesbah Talukder, Avantika Mann
Terbinafine has been a cornerstone in dermatophyte infection treatment. Despite its global efficacy, the emergence of terbinafine resistance raises concerns, requiring ongoing vigilance.This paper ...
-
An update on pharmacotherapies for colorectal cancer: 2023 and beyond Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-01 Mengou Zhu, Al B. Benson III
Colorectal cancer (CRC) is one of the most prevalent and lethal cancers worldwide. The treatment of metastatic colorectal cancer (mCRC) is difficult, and mCRC has a survival rate of only 13–17% com...
-
An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-01 Himil Mahadevia, Pedro Luiz Serrano Uson Junior, Jing Wang, Mitesh Borad, Hani Babiker
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1 (PD-1/PD-L1) pathway as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have demonstrated substantial pote...
-
Clinical guidance for choosing the right pharmacotherapy for migraine attacks Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-01 Izabela Domitrz
Migraine as headache attacks with autonomic symptoms is a serious condition and it is important to treat a single attack effectively in order to improve not only the patient’s quality of life at a ...
-
An expert opinion on the pharmacological interventions for Disruptive Mood Dysregulation Disorder (DMDD) Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-01 Laura Orsolini, Giulio Longo, Angelica Cicolini, Umberto Volpe
Disruptive Mood Dysregulation Disorder (DMDD) was officially introduced as a new diagnostic entity in the Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition (DSM-5), under the cate...
-
The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-01 Danielle S. Cha, Nicholas Kleine, Kayla M. Teopiz, Joshua D. Di Vincenzo, Roger Ho, Stephanie L. Galibert, Amrita Samra, Samuel P.M. Zilm, Rebekah H. Cha, Giacomo d’Andrea, Hartej Gill, Felicia Ceban, Shakila Meshkat, Sabrina Wong, Gia Han Le, Angela T.H Kwan, Joshua D. Rosenblat, Taeho Greg Rhee, Rodrigo B. Mansur, Roger S. McIntyre
Major depressive disorder (MDD) is a common and debilitating mental illness. Postpartum depression (PPD) impacts women globally and is one of the most common complications of childbirth that is und...
-
Advances in non-biological drugs for the treatment of rheumatoid arthritis Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-01 Aliki I. Venetsanopoulou, Paraskevi V. Voulgari, Alexandros A. Drosos
Rheumatoid arthritis (RA) is a complex autoimmune disease that affects millions of people worldwide, with a systemic impact. This review explores the role of non-biological conventional synthetic d...
-
Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment? Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-02-01 Mohammed Alsalmi, Jawad Al-Kassmy, Woojin Kang, Michael Palayew, Philippe Huot
Published in Expert Opinion on Pharmacotherapy (Vol. 25, No. 1, 2024)
-
Effectively addressing cardiovascular risk in people with metabolic-dysfunction associated fatty liver disease: not yet ready for prime time! Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-29 Theocharis Koufakis, Djordje S. Popovic, Christodoulos Papadopoulos, Olga Giouleme, Michael Doumas
Published in Expert Opinion on Pharmacotherapy (Ahead of Print, 2024)
-
Buspirone for the treatment of anxiety in Williams syndrome: a retrospective chart review study Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-22 Eva Shin, Danielle Renzi, Camila Canales, Caitlin Ravichandran, Christopher J. McDougle, Robyn P. Thom
Williams syndrome (WS) is a rare genetic disorder associated with a high prevalence of anxiety disorders. Evidence-based pharmacologic treatments for anxiety in WS are lacking. The purpose of this ...
-
Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now? Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-24 Mohamad Abou Chakra, Vignesh T. Packiam, Igor Duquesne, Michael Peyromaure, Ian M. McElree, Michael A. O’Donnell
The combination of intravesical gemcitabine (Gem) with docetaxel (Doce) or with mitomycin C (MMC) has been used in the primary setting as an alternative to Bacillus Calmette-Guerin (BCG) to treat h...
-
Expanding therapeutic options: lenacapavir + bictegravir as a potential treatment for HIV Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Jessica Doan, Shannon Brunzo-Hager, Brittany Satterly, Theodore James Cory
Treatment for people with HIV/AIDS has radically evolved since the introduction of the first antiretrovirals. One newly approved antiretroviral is lenacapavir, which targets the viral capsid. Lenac...
-
Choosing the appropriate pharmacotherapy for breast cancer during pregnancy: what needs to be considered? Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Diletta Favero, Laura Sabina Lapuchesky, Francesca Poggio, Simone Nardin, Marta Perachino, Luca Arecco, Graziana Scavone, Silvia Ottonello, Maria Maddalena Latocca, Roberto Borea, Silvia Puglisi, Maurizio Cosso, Alessandra Fozza, Stefano Spinaci, Matteo Lambertini
Breast cancer is the most commonly diagnosed malignancy during pregnancy. Breast cancer during pregnancy is a challenging clinical condition requiring proper and timely multidisciplinary management...
-
Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Hidekatsu Nakai, Noriomi Matsumura
Maintenance therapy with bevacizumab and the poly (ADP-ribose) polymerase (PARP) inhibitors olaparib and niraparib after first-line treatment of advanced ovarian cancer has been approved. However, ...
-
Pharmacological management of co-morbid obstructive sleep apnoea and insomnia Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Emma Thomas, Gorica Micic, Robert Adams, Danny J. Eckert
Clinical presentation of both insomnia and obstructive sleep apnea (COMISA) is common. Approximately 30% of clinical cohorts with OSA have insomnia symptoms and vice versa. The underlying pathophys...
-
Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Ilaria Mondo, Sophia Hannou, Patrizia D’Amelio
Osteoporosis, which is characterized by compromised bone density and heightened susceptibility to fractures, is a substantial public health concern, especially among the aging population. Underdiag...
-
Can we manage gut microbiome imbalances in patients with bipolar disorder with pharmacotherapy? Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Valerie H. Taylor, Vivek Kumar
A novel new area of exploration in the treatment of bipolar disorder is the gut brain axis. Studies have shown significant differences between the gut microbiome in those with bipolar disorder and ...
-
Use of sacubitril/valsartan in patients with heart failure: evidence from the real world Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Luis Fernando Valladales-Restrepo, Nicolás Sánchez-Ramírez, Andrés Felipe Usma-Valencia, Santiago Velásquez-Quirama, Manuela Henao-Martínez, Jorge Alejandro Castro-Rodriguez, Andrés Gaviria-Mendoza, Manuel Enrique Machado-Duque, Jorge Enrique Machado-Alba
To characterize the use of sacubitril/valsartan in a group of patients with heart failure in Colombia.Follow-up study of patients with heart failure who started sacubitril/valsartan and were affili...
-
What hinders individualized therapy plans for asthma patients? Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Ahmad Z. Al Meslamani
Published in Expert Opinion on Pharmacotherapy (Vol. 24, No. 18, 2023)
-
The landscape of pathophysiology guided therapeutic strategies for gout treatment Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Sai Heng Hao, Lin Yan Ye, Chang Yang
Gout is a common autoinflammatory disease caused by hyperuricemia with acute and/or chronic inflammation as well as tissue damage. Currently, urate-lowering therapy (ULT) and anti-inflammatory ther...
-
Novel pharmacotherapy for drug-induced immune hemolytic anemia Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Wilma Barcellini, Bruno Fattizzo
Published in Expert Opinion on Pharmacotherapy (Vol. 24, No. 18, 2023)
-
Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Sarah G. Bridgeman, Anna K. Martino, Lindsay C. Strowd
New biologic and small molecule therapeutics have emerged for the treatment of moderate-to-severe atopic dermatitis (AD), including oral Janus kinase (JAK) inhibitors such as baricitinib. While JAK...
-
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Toshinobu Hayashi, Mototsugu Shimokawa, Koichi Matsuo, Kei Kawada, Takafumi Nakano, Takashi Egawa
Chemotherapy-induced nausea and vomiting (CINV) is an ongoing problem. While effectiveness of triplet antiemetic regimens in the delayed CINV phase (24–120 hours after administration of chemotherap...
-
Current optimal pharmacologic therapies for overactive bladder Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Yuan-Hong Jiang, Hann-Chorng Kuo
Overactive bladder (OAB) is a common syndrome in adults. Current pharmacologic treatment includes antimuscarinic agents and β-3 adrenoceptor agonists. For non-responders to oral medication, intrave...
-
The pharmacological management of treatment-resistant depression: what does the future hold? Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Alessandro Serretti
Published in Expert Opinion on Pharmacotherapy (Vol. 24, No. 18, 2023)
-
Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Maria Gabriella Matera, Barbara Rinaldi, Luigino Calzetta, Paola Rogliani, Mario Cazzola
Strong scientific evidence and large experience support the use of β2-agonists for the symptomatic alleviation of COPD. Therefore, there is considerable effort in discovering highly potent and sele...
-
An update on the current and emerging pharmacotherapies for basal cell carcinomas Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Alessia Villani, Massimiliano Scalvenzi, Giuseppe Micali, Fabrizio Martora, Francesco Cillo, Flavia Raia, Luca Potestio
Despite surgical approach is still the mainstay for basal cell carcinoma (BCC) management, several issues may limit the use of this technique, leading to the need for new treatments to offer patien...
-
Longitudinal efficacy of Ertugliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Parvej Khan, Shubhashree Venkatesh, Rizwana Parveen, Pinki Mishra, Seema Jain, Nidhi Agarwal
Ertugliflozin, a sodium-glucose cotransporter-2 inhibitor, seems to improve glycemic control in type 2 diabetes mellitus (T2DM). We aim to evaluate the efficacy of Ertugliflozin across multiple tim...
-
Psychedelics for treatment resistant depression: are they game changers? Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Michail Kalfas, Rosie H. Taylor, Dimosthenis Tsapekos, Allan H. Young
A new era of treatment for adults with treatment-resistant depression (TRD), which involves psychedelic substances, is dawning. Emerging evidence indicates that psychedelics can exert antidepressan...
-
Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Ashling Courtney, Daranporn Triwongwarant, Ivana Chim, Samantha Eisman, Rodney Sinclair
Published in Expert Opinion on Pharmacotherapy (Vol. 24, No. 18, 2023)
-
Ivosidenib in acute myeloid leukemia Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Antonella Bruzzese, Caterina Labanca, Enrica Antonia Martino, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Antonino Neri, Annalisa Imovilli, Fortunato Morabito, Ernesto Vigna, Massimo Gentile
Traditional treatment strategies for acute myeloid leukemia (AML) have primarily relied on standard chemotherapy regimens for four decades. Indeed, the landscape of AML therapy has evolved substant...
-
Exploring the nexus of binge eating disorder (BED), New Psychoactive Substances (NPS), and misuse of pharmaceuticals: charting a path forward Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Stefania Chiappini, G. Duccio Papanti Pelletier, Rachel Vickers-Smith, John M. Corkery, Amira Guirguis, Giovanni Martinotti, Fabrizio Schifano
Published in Expert Opinion on Pharmacotherapy (Vol. 24, No. 18, 2023)
-
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Brian Tomlinson, Yan-Hong Li
Patients with type 2 diabetes (T2D) usually show progressive deterioration in glycemic control and sequential additions of therapy are generally needed. Many new options for glucose lowering therap...
-
Recent advances in drug treatments for dry eye disease Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Giulia Coco, Giacomo Ambrosini, Silvia Poletti, Laura Antonia Meliante, Andrea Taloni, Vincenzo Scorcia, Giuseppe Giannaccare
Dry eye disease (DED) is a common ocular condition with a significant impact on patients’ quality of life. Conventional treatments include behavioral changes, tear substitutes, and anti-inflammator...
-
Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Mithum Kularatne, Athénaïs Boucly, Laurent Savale, Sabina Solinas, Céline Cheron, Anne Roche, Mitja Jevnikar, Xavier Jaïs, David Montani, Marc Humbert, Olivier Sitbon
Pulmonary arterial hypertension (PAH) is a severe, progressive pulmonary vasculopathy (Group 1 Pulmonary Hypertension (PH)) that complicates the course of many connective tissue diseases (CTD). Det...
-
The impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19 Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Joseph E Blais, Peng Wu
Published in Expert Opinion on Pharmacotherapy (Vol. 24, No. 18, 2023)
-
Real-world efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Mohamad Abou Chakra, Vignesh T Packiam, Michael A O’Donnell
Failure, intolerance, or shortage of bacillus Calmette-Guerin (BCG) treatment for patients with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) leave many facing the prospect of radical c...
-
Response to: “the impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19” Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Matteo Bassetti, Giorgia Brucci, Antonio Vena, Daniele Roberto Giacobbe
Published in Expert Opinion on Pharmacotherapy (Vol. 24, No. 18, 2023)
-
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Sagar Dholariya, Siddhartha Dutta, Ragini Singh, Deepak Parchwani, Amit Sonagra, Mehul Kaliya
This study assessed the clinical safety and efficacy of bexagliflozin, a sodium-glucose cotransporter 2(SGLT2) inhibitor, in managing glycemia among patients with type 2 diabetes mellitus (T2DM).We...
-
Liposomal drug formulations for treatment of hematological malignancies Expert Opin. Pharmacother. (IF 3.2) Pub Date : 2024-01-05 Daniel Cacic Limi, Håkon Reikvam
Published in Expert Opinion on Pharmacotherapy (Vol. 24, No. 18, 2023)